Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 2
2011 1
2012 3
2013 2
2014 7
2015 3
2016 3
2017 8
2018 6
2019 5
2020 6
2021 2
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy.
Wen T, Barham W, Li Y, Zhang H, Gicobi JK, Hirdler JB, Liu X, Ham H, Peterson Martinez KE, Lucien F, Lavoie RR, Li H, Correia C, Monie DD, An Z, Harrington SM, Wu X, Guo R, Dronca RS, Mansfield AS, Yan Y, Markovic SN, Park SS, Sun J, Qin H, Liu MC, Vasmatzis G, Billadeau DD, Dong H. Wen T, et al. Among authors: dronca rs. Cancer Immunol Res. 2022 Feb;10(2):162-181. doi: 10.1158/2326-6066.CIR-21-0539. Epub 2021 Dec 15. Cancer Immunol Res. 2022. PMID: 34911739 Free PMC article.
Immune Checkpoint Inhibitor Toxicities.
Marin-Acevedo JA, Chirila RM, Dronca RS. Marin-Acevedo JA, et al. Among authors: dronca rs. Mayo Clin Proc. 2019 Jul;94(7):1321-1329. doi: 10.1016/j.mayocp.2019.03.012. Mayo Clin Proc. 2019. PMID: 31272574 Review.
The dynamic human immune response to cancer: it might just be rocket science.
Holtan SG, Dronca RS, Nevala WK, Porrata LF, Mansfield AS, Block MS, Leontovich AA, Grotz TE, Turner JD, Frisch HP, Markovic SN. Holtan SG, et al. Among authors: dronca rs. Immunotherapy. 2011 Sep;3(9):1021-4. doi: 10.2217/imt.11.109. Immunotherapy. 2011. PMID: 21913823 Free article. No abstract available.
Rare presentations of primary melanoma and special populations: a systematic review.
Kottschade LA, Grotz TE, Dronca RS, Salomao DR, Pulido JS, Wasif N, Jakub JW, Bagaria SP, Kumar R, Kaur JS, Morita SY, Moran SL, Nguyen JT, Nguyen EC, Hand JL, Erickson LA, Brewer JD, Baum CL, Miller RC, Swanson DL, Lowe V, Markovic SN. Kottschade LA, et al. Among authors: dronca rs. Am J Clin Oncol. 2014 Dec;37(6):635-41. doi: 10.1097/COC.0b013e3182868e82. Am J Clin Oncol. 2014. PMID: 23563206 Free PMC article. Review.
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
Hieken TJ, Nelson GD, Flotte TJ, Grewal EP, Chen J, McWilliams RR, Kottschade LA, Yang L, Domingo-Musibay E, Dronca RS, Yan Y, Markovic SN, Dimou A, Montane HN, Erskine CL, Piltin MA, Price DL, Khariwala SS, Hui J, Strand CA, Harrington SM, Suman VJ, Dong H, Block MS. Hieken TJ, et al. Among authors: dronca rs. Nat Commun. 2024 Feb 16;15(1):1430. doi: 10.1038/s41467-024-45798-8. Nat Commun. 2024. PMID: 38365756 Free PMC article. Clinical Trial.
49 results